STOCK TITAN

Sale of 11,345 IDEXX (NASDAQ: IDXX) shares planned under Rule 144

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A holder of IDEXX Laboratories common stock has filed a notice of proposed sale under Rule 144. The filing covers 11,345 shares of common stock, with an aggregate market value of 7,336,994.15, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 02/10/2026.

These 11,345 shares were acquired on 02/10/2026 via a stock option exercise from the issuer, paid in cash on the same date. The filing notes that 79,851,330 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for IDXX disclose?

The Form 144 shows a planned sale of 11,345 IDEXX common shares under Rule 144. These shares, valued in total at 7,336,994.15, are to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC around 02/10/2026.

How many IDEXX (IDXX) shares are planned to be sold and at what value?

The notice covers the proposed sale of 11,345 IDEXX common shares with an aggregate market value of 7,336,994.15. This reflects the estimated total market value of the transaction at the time the Form 144 was prepared.

How were the IDEXX shares in the Form 144 acquired?

The 11,345 IDEXX common shares were acquired on 02/10/2026 through a stock option exercise from the issuer. The filing states the exercise was paid for in cash, with the payment date also listed as 02/10/2026.

Which broker and exchange are involved in the IDXX Form 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. The Form 144 indicates that the 11,345 IDEXX common shares are intended to be sold on the NASDAQ stock market around 02/10/2026.

How many IDEXX shares are outstanding compared to the amount in the Form 144?

The filing states that 79,851,330 IDEXX common shares were outstanding. The planned Rule 144 sale covers 11,345 shares, giving readers context on the relative size of this transaction versus the total shares outstanding.

What representation does the seller make in the IDXX Form 144?

By signing the notice, the seller represents that they do not know of any material adverse information about IDEXX’s current or prospective operations that has not been publicly disclosed, as required under the Rule 144 filing instructions.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

49.28B
79.30M
0.68%
97.52%
2.56%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK